Monoclonal Antibody, Human Interleukin 6 Inhibitors

Human interleukin-6 (IL-6) inhibitor monoclonal antibodies are a therapeutic class of biologic disease-modifying agents that suppress systemic inflammation by selectively blocking the IL-6 signaling pathway Agents in this class work either by directly binding and neutralizing the circulating IL-6 cytokine (such as siltuximab) or by binding to soluble and membrane-bound IL-6 receptors to prevent cytokine engagement (such as tocilizumab and sarilumab) By interrupting downstream inflammatory cascad...

Human interleukin-6 (IL-6) inhibitor monoclonal antibodies are a therapeutic class of biologic disease-modifying agents that suppress systemic inflammation by selectively blocking the IL-6 signaling pathway Agents in this class work either by directly binding and neutralizing the circulating IL-6 cytokine (such as siltuximab) or by binding to soluble and membrane-bound IL-6 receptors to prevent cytokine engagement (such as tocilizumab and sarilumab)

Agents in this class work either by directly binding and neutralizing the circulating IL-6 cytokine (such as siltuximab) or by binding to soluble and membrane-bound IL-6 receptors to prevent cytokine engagement (such as tocilizumab and sarilumab)

By interrupting downstream inflammatory cascades and B-cell activation, these biologics are primarily utilized to treat moderate-to-severe autoimmune and rheumatologic disorders—including rheumatoid arthritis, giant cell arteritis, and juvenile idiopathic arthritis—as well as severe hyperinflammatory states like cytokine release syndrome and idiopathic multicentric Castleman disease

By interrupting downstream inflammatory cascades and B-cell activation, these biologics are primarily utilized to treat moderate-to-severe autoimmune and rheumatologic disorders—including rheumatoid arthritis, giant cell arteritis, and juvenile idiopathic arthritis—as well as severe hyperinflammatory states like cytokine release syndrome and idiopathic multicentric Castleman disease